Tezepelumab, a monoclonal antibody that targets thymic stromal lymphopoietin (TSLP) preventing interaction with its receptor thus blocks upstream activation of type 2 innate lymphoid cells (ILC2) finally blocking the release of IL-5, IL-4, IL-13, treats T-helper type 2 cell endotype High subtype asthma effectively and is approved for patients > 12 years with severe asthma regardless of serum eosinophils, IgE, and FeNO levels [74]. Here, IL13 is linked to asthma.